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Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for 
prognostic association of circulating tumor cells in gastroesophageal cancer 
Abstract 
AIM: To demonstrate the feasibility of cryopreservation of peripheral blood mononuclear cells (PBMCs) 
for prognostic circulating tumor cell (CTC) detection in gastroesophageal cancer. 
METHODS: Using 7.5 mL blood samples collected in EDTA tubes from patients with gastroesopheagal 
adenocarcinoma, CTCs were isolated by epithelial cell adhesion molecule based immunomagnetic 
capture using the IsoFlux platform. Paired specimens taken during the same blood draw (n = 15) were 
used to compare number of CTCs isolated from fresh and cryopreserved PBMCs. Blood samples were 
processed within 24 h to recover the PBMC fraction, with PBMCs used for fresh analysis immediately 
processed for CTC isolation. Cryopreservation of PBMCs lasted from 2 wk to 25.2 mo (median 14.6 mo). 
CTCs isolated from pre-treatment cryopreserved PBMCs (n = 43) were examined for associations with 
clinicopathological variables and survival outcomes. 
RESULTS: While there was a significant trend to a decrease in CTC numbers associated with 
cryopreserved specimens (mean number of CTCs 34.4 vs 51.5, P = 0.04), this was predominately in 
samples with a total CTC count of > 50, with low CTC count samples less affected (P = 0.06). There was 
no significant association between the duration of cryopreservation and number of CTCs. In 
cryopreserved PBMCs from patient samples prior to treatment, a high CTC count ( > 17) was associated 
with poorer overall survival (OS) (n = 43, HR = 4.4, 95%CI: 1.7-11.7, P = 0.0013). In multivariate analysis, 
after controlling for sex, age, stage, ECOG performance status, and primary tumor location, a high CTC 
count remained significantly associated with a poorer OS (HR = 3.7, 95%CI: 1.2-12.4, P = 0.03). 
CONCLUSION: PBMC cryopreservation for delayed CTC isolation is a valid strategy to assist with sample 
collection, transporting and processing. 
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Abstract
AIM
To demonstrate the feasibility of cryopreservation 
of peripheral blood mononuclear cells (PBMCs) for 
prognostic circulating tumor cell (CTC) detection in 
gastroesophageal cancer.
METHODS
Using 7.5 mL blood samples collected in EDTA tubes 
from patients with gastroesopheagal adenocarcinoma, 
CTCs were isolated by epithelial cell adhesion molecule 
based immunomagnetic capture using the IsoFlux 
platform. Paired specimens taken during the same 
blood draw (n  = 15) were used to compare number 
of CTCs isolated from fresh and cryopreserved PBMCs. 
Blood samples were processed within 24 h to recover 
the PBMC fraction, with PBMCs used for fresh analysis 
immediately processed for CTC isolation. Cryopre-
servation of PBMCs lasted from 2 wk to 25.2 mo 
(median 14.6 mo). CTCs isolated from pre-treatment 
cryopreserved PBMCs (n  = 43) were examined for 
associations with clinicopathological variables and 
survival outcomes.
RESULTS
While there was a significant trend to a decrease in 
CTC numbers associated with cryopreserved specimens 
(mean number of CTCs 34.4 vs  51.5, P  = 0.04), this 
was predominately in samples with a total CTC count 
of > 50, with low CTC count samples less affected (P 
= 0.06). There was no significant association between 
the duration of cryopreservation and number of CTCs. 
In cryopreserved PBMCs from patient samples prior 
to treatment, a high CTC count (> 17) was associated 
with poorer overall survival (OS) (n  = 43, HR = 4.4, 
95%CI: 1.7-11.7, P  = 0.0013). In multivariate analysis, 
after controlling for sex, age, stage, ECOG performance 
status, and primary tumor location, a high CTC count 
remained significantly associated with a poorer OS (HR 
= 3.7, 95%CI: 1.2-12.4, P  = 0.03). 
CONCLUSION
PBMC cryopreservation for delayed CTC isolation is a 
valid strategy to assist with sample collection, trans-
porting and processing.
Key words: Cryopreservation; Circulating tumor cells; 
Liquid biopsy; Gastroesophageal cancer; Gastric cancer
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This study demonstrates a novel and robust 
protocol for the cryopreservation and thawing of patient 
blood samples, demonstrating reliable circulating tumor 
cell isolation and characterisation after the long term 
storage of patient samples. Using the largest patient 
cohort reported to date, we validated our method by 
confirming the independent prognostic association of 
circulating tumor cell (CTC) enumeration from cryopre-
served peripheral blood mononuclear cells. Cryopre-
servation may assist with the wider incorporation of 
CTC collection and analysis in biobanking, retrospec-
tive studies, and large international clinical trials, by 
facilitating specimen storage, bulk transporting, and 
batch processing.
Brungs D, Lynch D, Luk AW, Minaei E, Ranson M, Aghmesheh 
M, Vine KL, Carolan M, Jaber M, de Souza P, Becker TM. 
Cryopreservation for delayed circulating tumor cell isolation 
is a valid strategy for prognostic association of circulating 
tumor cells in gastroesophageal cancer. World J Gastroenterol 
2018; 24(7): 810-818  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v24/i7/810.htm  DOI: http://dx.doi.
org/10.3748/wjg.v24.i7.810
INTRODUCTION
Circulating tumor cell (CTC) analysis continues to be a 
rapidly developing field in oncology, offering a promising 
tool to both prognosticate and guide managements for 
patients[1]. Despite recent advancements in the field, 
one persisting challenge to the widespread adoption 
of CTC analysis for translational clinical trials or routine 
clinical care is the limited time frame considered 
best for blood processing and CTC isolation. Usually 
fresh blood is processed for CTCs within 24 h after 
blood draw, requiring prompt transfer to specialised 
centres for CTC isolation and analysis, which offers 
significant logistical challenges[2]. To overcome this 
issue, some studies use blood collection tubes that 
contain fixatives. Fixation of blood samples can allow 
CTC processing delayed by several days which has 
proven very useful for some CTC analyses[3,4]. However, 
fixatives may interfere with down-stream molecular 
analyses that require isolation of nucleic acids[5]. An 
alternative is the use of cryopreservation protocols for 
peripheral blood mononuclear cells (PBMCs) to allow 
delayed CTC isolation from these cells followed by CTC 
analysis. Cryopreservation should overcome fixation 
related analysis limitations and allow far more flexible 
time frames for batched CTC processing. However, a 
defined, robust cryopreservation protocol that is proven 
to enable analysis of the same or at least a relevant 
proportion of CTCs to that found in fresh samples, 
needs to be adopted and confirmation is needed 
whether cryopreserved CTCs can still predict disease 
outcome.
The advantage of cryopreservation of PBMCs is that 
it requires only minimal local processing, possible in 
most diagnostic settings, as well as feasible cryostorage 
and frozen transport of PBMC samples.
While there are a large number of approaches used 
to isolate and identify circulating tumor cells (recently 
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reviewed by van der Toom et al[6]), the best established 
and most widely used is the CellSearchTM system 
(Menarini-Silicon Biosystems), which uses positive 
immunomagnetic isolation of epithelial cell adhesion 
molecule (EpCAM, an epithelial cell marker) expressing 
cells followed by cytokeratin (CK), CD45, and DAPI 
staining[2]. The CTCs are then identified with automated 
immunofluorescence microscopy, defined by an EpCAM/
CK/DAPI positive and CD45 negative phenotype. Cell 
Search CTC counts have shown to be prognostic in 
large patient series in a variety of cancers[7-9], including 
gastroesophageal cancer[10-12], but the instrument offers 
limited sensitivity in resectable gastroesophageal cancer, 
with CTCs detected in less than 15% of patients[10,13]. 
The IsoFlux system (Fluxion) uses a similar definition 
of CTCs to CellSearch (EpCAM/CK/DAPI positive, 
CD45 negative phenotype), but has shown a greater 
sensitivity for CTC detection[14-16]. This platform uses 
EpCAM targeted immunomagnetic isolation of CTCs 
within a microfluidic setting, improving isolation of CTCs 
with lower EpCAM expression, minimising leukocyte 
contamination, and allowing downstream applications 
including staining, enumeration, or sequencing, as 
shown for fresh blood samples[16].
Here, we use a viable method of PBMC cryopre-
servation that allows subsequent isolation and immu-
nocytochemical analysis of CTCs. We demonstrate 
the feasibility of PBMC cryopreservation for delayed 
CTC isolation using paired cryopreserved and freshly 
processed blood samples drawn at the same time 
from patients with gastroesophageal adenocarcinoma. 
Importantly, we also provide data confirming that 
cryopreserved CTCs remain clinically applicable as a 
circulating prognostic marker for overall survival (OS).
MATERIALS AND METHODS
Patient population
Blood samples were collected from patients with 
histologically confirmed distal oesophageal, gastroe-
sophageal junction, or gastric adenocarcinomas treated 
at Wollongong Hospital, Australia. Blood samples were 
collected in 7.5 mL EDTA Vacutainer tubes (Sarstedt 
AG & Co.) and maintained at room temperature until 
processing.
In the initial cohort (Cohort 1) to confirm the feasi-
bility of cryopreservation, 15 patients with gastroe-
sophageal carcinomas had 2 specimens taken during 
the one blood draw, one processed within 24 h (“fresh” 
specimen), and one cryopreserved with delayed CTC 
isolation and analysis (“cryopreserved” specimen). Pre-
treatment blood samples were cryopreserved from a 
second, larger cohort of patients for correlation with 
clinical outcomes (Cohort 2). The study was approved 
by South Western Sydney Local Health District Human 
Research Ethics Committee (Project Number 15/072). 
A written informed consent was obtained from each 
participant before sample collection.
Sample preparation
Blood samples were processed within 24 h to recover 
the PBMC fraction using 50 mL SepMate tubes and 
Lymphoprep according to manufacturer’s instructions 
(Stemcell Technologies, Vancouver, BC, Canada).
PBMCs used for fresh analysis were resuspended in 
Isoflux Binding Buffer and immediately processed for 
CTC isolation (see below).
PBMCs for cryopreservation were well resuspended 
in 1 mL of diluted plasma (the supernatant of the 
PBMC preparation from the matching patient) with the 
addition of 7.5% final DMSO, and stored at -80 ℃ until 
further processing. Cryopreserved samples were thawed 
according to the protocol from Fluxion Biosciences, San 
Francisco, California, United States[17]. In brief, warmed 
(37 ℃) thawing buffer, consisting of RPMI 1640 with 
10% Fetal Bovine Serum (FBS, Bovogen Biologicals, 
Australia) and 50 Unit/mL Benzonase (Sigma-Aldrich, 
Germany), was added to thawed samples, washed once 
in thawing buffer, and resuspended in IsoFlux Binding 
Buffer with 5% FBS. 
Circulating tumor cell isolation, staining, and imaging
As per the Fluxion protocol, immunomagnetic beads 
preconjugated with anti-EpCAM antibodies (CTC 
Enrichment Kit; Fluxion Biosciences Inc) were added 
to PBMCs suspended in IsoFlux Binding Buffer, and 
incubated for 90 min at 4 ℃ with passive mixing on a 
rotator. Samples were then loaded into the sample well 
of the microfluidic cartridge and underwent immuno-
magnetic isolation of CTCs with the IsoFlux using the 
standard protocol (Fluxion Biosciences Inc).
Recovered CTCs were blocked with a final concen-
tration of 1.2 µg/µL mouse IgG in binding buffer (Jackson 
ImmunoResearch, Baltimore, PA, United States) for 
30 min, washed and fixed in fixing solution (Fluxion 
Biosciences Inc). The CTCs were then blocked in 10% 
FBS in binding buffer for 15 min, then underwent immu-
nofluorence staining for anti-CD45 antibody conjugated 
to Alexa Fluor 647 (Biolegend, Clone HI30). The 
CTCs were also stained for urokinase plasminogen 
activator receptor (uPAR, CD87), a key receptor in the 
plasminogen activator system and clinically relevant 
biomarker in primary gastroesophageal cancer[18], using 
anti-uPAR antibody conjugated to AF594 (ThermoFischer, 
Clone R4). After permeabilization with 0.1% Triton 
X-100, cells were probed with anti-cytokeratin antibody 
conjugated to FITC (Sigma-Aldrich, Clone PCK-26). CTCs 
were finally stained with Hoechst and mounted using 
Isoflux mounting media to 24-well glass bottom plates 
(MoBioTec, Goettingen, Germany) for imaging. 
Imaging was performed with an inverted epifluo-
rescence microscope (Leica DMi8, Leica Microsystems 
Pty Ltd) using the Leica Application Suite. Cells were 
considered CTCs if they were CK positive, CD45 
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similar to fresh samples (Figure 1). There was a 
significant difference between CTC numbers isolated 
from the cryopreserved samples compared to fresh 
samples (mean number of CTCs 34.4 cryopreserved vs 
51.5 fresh, P = 0.04, Figure 2), however this difference 
was predominately attributable to a larger fall in CTC 
numbers in samples with very high CTC counts (> 50 
CTCs in the fresh specimen). There was no significant 
difference in CTC count between cryopreserved and 
fresh samples for specimens with CTC count less than 
50 (n = 11 patients, mean number of CTCs 10.7 vs 
16.3, P = 0.06). Thus CTC loss by cryopreservation in 
patient samples with low CTC counts appears relatively 
minor (mean proportion of CTCs lost in cryopreserved 
samples = 23.95%).
Cryopreserved circulating tumor cell and clinical 
outcomes (cohort 2)
A larger cohort of 43 gastroesophageal cancer 
patients (cohort 2) was analyzed to validate whether 
detectable CTC counts post cryopreservation correlated 
to disease outcomes. All patient samples were taken 
prior to treatment commencement and had undergone 
cryopreservation before CTC isolation. Cohort 2 included 
the 10 treatment naive patients from cohort 1. Patient 
characteristics of cohort 2 are summarised in Table 1. 
Twenty-four patients had resectable disease (Stage 
Ⅱ or Ⅲ). Post CTC evaluation, 11 of these patients 
received neoadjuvant chemoradiotherapy prior to 
resection (CROSS regimen), 3 received perioperative 
chemotherapy (MAGIC regimen), and 10 had surgery 
alone. Nineteen patients had metastatic disease (stage 
Ⅳ). Most of these patients received chemotherapy 
(7 patients: platinum and capecitabine doublet, 3 
patients: anthracycline, capecitabine, and platinum 
triplet, 1 patient: irinotecan or paclitaxel monotherapy), 
immunotherapy (2 patients), and 6 patients received no 
active systemic treatments. 
CTCs were detected in 42/43 patients (95.5%), 
negative, nucleated and morphologically intact. The 
proportion of uPAR positive CTCs was recorded.  
Statistical analysis
The CTC recovery from matched cryopreserved and 
fresh samples were compared with the paired t-test. 
Correlation between cryopreservation time and CTC 
number was described with a Pearson correlation 
coefficient, and the Fisher exact test and t-test were 
used to compare the status of CTCs with categorical 
clinicopathologic factors. 
For survival analyses, in the absence of established 
cut-offs for prognostic CTC numbers, the median CTC 
count (17) was used as the discriminator between high 
and low CTC counts. Survival analyses are conducted 
using Kaplan-Meier methods, with median survival 
reported. Unadjusted and multivariable Cox proportional 
hazards regression analyses were used to estimate the 
association between CTC counts and survival, and to 
calculate corresponding hazard ratios (HRs) and 95% 
confidence intervals (CIs). The following variables were 
included in the multivariate model: age, sex, ECOG, 
TNM stage, primary tumor location, and CTC count. 
All statistical analyses were performed using SAS 9.2 
software (SAS Institute, Inc., Cary, NC, United States). 
RESULTS
Matched fresh and cryopreserved specimens (cohort 1)
Matching parallel blood samples, collected from 15 
gastroesophageal cancer patients (10 patients had 
blood taken prior to treatment, 5 patients were already 
on treatment), that had either been cryopreserved 
before CTC processing or were processed fresh, were 
compared. Cryopreservation of PBMCs lasted from 2 wk 
to 25.2 mo (median 14.6 mo). There was no significant 
correlation between cryopreservation time and CTC 
number (Pearson r -0.25, P = 0.09). CTCs isolated 
from cryopreserved samples appeared morphologically 
DAPI
Fresh
CK CD45 uPAR Merged
Cryopreserved 20 µm
Figure 1  Representative images of circulating tumor cell isolation from fresh and cryopreserved samples demonstrating preservation of leukocyte and 
circulating tumor cell morphology. The fresh sample demonstrates a nucleated CK+/CD45- CTC which is uPAR negative, as well as a CK-/CD45+ leukocyte. The 
cryopreserved sample shows a uPAR positive CTC. CTC: Circulating tumor cell.
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with a median CTC of 17 (interquartile range 8-38). 
Patients with metastatic disease had a higher number 
of CTCs than those with resectable disease (Figure 3, 
mean CTC count 53.8 vs 15.8, P = 0.0013).
Currently there are no established cut-offs for 
prognostic CTC numbers detected using the IsoFlux 
in gastroesophageal adenocarcinoma. Therefore we 
opted to divide our patients by their CTC counts, above 
versus equal or lower than the median CTC count, 
to test for any correlation with clinical outcomes. 
Patients with a high CTC count (> 17) had a poorer 
OS than those with a lower CTC count (≤ 17) (Figure 
4, median OS 2.8 mo vs 23.2 mo, HR = 4.4, 95%CI: 
1.7-11.7, P = 0.0013). In multivariate analysis, after 
controlling for sex, age, stage, ECOG performance 
status, and primary tumor location, a high CTC count 
remained an independent prognostic factor associated 
with poor OS (Table 2, HR = 3.7, 95%CI: 1.2-12.4, 
P = 0.03). This association was stronger when the 
analysis was restricted to patients with metastatic 
disease (n = 19, HR = 5.5, 95%CI: 1.2-25.5, P = 0.01), 
but not observed in patients with resectable disease 
(n = 24, P = 0.39), although a high CTC count (> 17) 
was associated with a non-significant trend to shorter 
recurrence free survival in these patients (HR = 3.1, 
95%CI: 0.8-12.6, P = 0.09). 
Most patients had some uPAR positive CTCs (40/43, 
93.0%), however the proportion of uPAR positive CTCs 
was similar between patients with localised and meta-
static disease (mean proportion uPAR positive CTCs 
48.8% vs 47.7% respectively, P = 0.89), and there was 
no association with survival outcomes (Supplementary 
Table 1  Characteristics of patients in cohort 2 n  (%)
CTC count
All patients Low (CTC ≤ 17) High (CTC > 17)
n  = 43 n  = 23 n  = 20
Age
   Mean (range) 64 (39-89) 65 (39-89) 64 (48-83)
Sex
   Male 32 (74.4) 15 (65.2) 20 (85.0)
   Female 11 (25.6) 8 (34.8) 3 (15.0)
ECOG
   0-1 36 (83.7) 22 (95.6) 14 (70.0)
   2-4 7 (16.3) 1 (4.3) 6 (30.0)
Primary tumor location
   Distal oesophageal 12 (27.9) 8 (34.8) 4 (20.0)
   Gastroesophageal junction 14 (32.6) 4 (17.4) 10 (50.0)
   Gastric 17 (37.5) 11 (47.8) 6 (30.0)
Stage
   Ⅱ 18 (41.9) 13 (56.5) 5 (25.0)
   Ⅲ 6 (14.0) 4 (17.4) 2 (10.0)
   Ⅳ 19 (44.2) 6 (26.1) 13 (65.0)
CTC: Circulating tumor cell; ECOG: Eastern cooperative oncology group performance status.












Figure 2  Circulating tumor cell enumeration by processing method. 
Mean number of CTCs isolated in the fresh specimens were higher than in the 
matched cryopreserved sample (mean difference in CTCs 17.1 95%CI: 0.7-33.6, 
P = 0.043). This difference was mostly driven by larger falls in CTC counts in 
samples with high numbers of CTCs (> 50 CTCs in fresh samples), with no 
significant difference in CTC counts for samples with less than 50 CTC in the 
fresh specimen (P = 0.06).















Figure 3  Circulating tumor cell count by stage. CTC processing post 
cryopreservation produced a higher mean CTC count in metastatic patients 
compared to the resectable patients (mean CTC in metastatic 53.8 vs 
resectable 15.8, P = 0.0013). CTC: Circulating tumor cell.
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Figure 1, median OS 17.0 mo vs 12.8 mo, P = 0.6).
DISCUSSION
In this study we report the reliable isolation, immuno-
cytochemical identification, and enumeration of gastroe-
sophageal cancer CTCs from cryopreserved PBMCs 
using the IsoFlux platform. The included cohort is the 
largest reported study analysing cryopreservation of 
patient PBMCs for CTC detection. Our data confirms 
that CTCs isolated from cryopreserved samples remain 
an independent prognostic factor associated with OS.
The timely processing of patient samples for CTC 
isolation, usually is recommended within 24 h for most 
isolation methods[19], presenting significant logistical 
challenges for researchers and prohibits inclusion of 
patients from remote areas into clinical trials that would 
rely on CTCs as outcome measures. This is mainly be-
cause current methods of CTC analysis require signifi-
cant expertise, instrumentation, time and laboratory 
resources, usually performed in specialised research 
centres. Protocols using isolation of CTCs from cryop-
reserved specimens would require some basic proces-
sing and cryopreservation at the site of blood draw, but 
offer many advantages, including the ability to biobank 
patient samples for prolonged periods of time before 
central processing. This would be a huge benefit for 
larger scale clinical trials as it would allow inclusion of 
geographically separated sites. 
Previous work has shown that the immunochemical 
properties of CK, EpCAM and CD45, central to the 
isolation and identification of CTCs, are not affected 
by cryopreservation and thawing[20,21]. In agreement, 
our results demonstrate a similar morphological and 
immunofluorescent profile between cryopreserved 
and fresh CTCs and leukocytes, suggesting current 
techniques are suitable for cryopreserved samples. 
This approach is further supported by other work 
showing close concordance in genetic alterations seen 
on paired fresh and frozen CTCs[21].
Our results also show that enumeration of CTCs 
isolated from cryopreserved PMBCs is a valid prognostic 
biomarker in gastroesophageal cancer. Patients with 
metastatic disease had a significantly higher number 
of CTCs than those with resectable disease (mean CTC 
count 53.8 vs 15.8, P = 0.0013). Moreover, patients 
with a high CTC count (> 17) had a much poorer OS 
than those with a lower CTC count (≤ 17) (HR = 4.4, 
P = 0.0013). High CTC count remained significant in 
the multivariate analysis as an independent predictor 
of poorer OS (HR = 3.7, P = 0.03), after controlling for 
age, ECOG, sex, stage and primary tumour location, 
particularly when analysis was restricted to patients with 
metastatic disease only (HR = 5.5, P = 0.01). These 
results are concordant with other studies which confirm 
CTC enumeration as an important prognostic factor in 
gastroesophageal cancer[10-12]. 
Given our previous findings that the uPA system is a 
clinically relevant biomarker in primary gastroesophageal 
cancer[18], we undertook and successfully probed for 
uPAR expression in CTCs derived from cryopreserved 
and fresh samples. We previously have shown that 
higher expression of uPA, uPAR and PAI-1 in the 
primary tumour is associated with higher risk disease 
and poorer prognosis. However, in this study, there 
was no correlation between CTC uPAR expression with 
disease parameters. This suggests that the selection of 
epithelial (EpCAM-positive) CTCs might have affected 
any correlation of uPAR with patient outcome, as 
CTCs that present mesenchymal phenotypes, such as 
Table 2  Univariate and multivariate analysis for overall survival for cohort 2 (n  = 43)
Univariate Multivariate
Factor HR (95%CI) P  value HR (95%CI) P  value
CTC count (high vs low) 4.4 (1.7-11.7) 0.001 3.7 (1.2-12.4) 0.03
Age (≥ 65 vs <65 yr old) 0.7 (0.3-1.8) 0.46 1.0 (0.9-1.1) 0.76
ECOG (2-4 vs 0-1) 7.2 (2.2-23.7) 0.0002 2.3 (0.5-10.1) 0.14
Sex (male vs female) 1.2 (0.4-3.8) 0.7 0.7 (0.2-2.1) 0.49
Stage (Ⅳ vs Ⅱ-Ⅲ) 10.0 (3.3-30.8) < 0.0001 9.9 (2.9-33.8) 0.0003
Primary tumor location (gastric vs oesophageal/GOJ) 0.3 (0.1-1.01) 0.05 0.4 (0.2-1.6) 0.22
Significant values are italicised. In both univariate and multivariate analysis, a high CTC count (> 17) remained statistically significant as an independent 
factor associated with poorer overall survival. CTC: Circulating tumor cell; ECOG: Eastern cooperative oncology group performance status; GOJ: 
Gastroesophageal junction.















Figure 4  Overall survival by circulating tumor cell count. Patients with > 
17 CTCs isolated from cryopreserved specimens had a poorer overall survival 
compared to those with ≤ 17 CTCs (median OS 2.8 mo vs 23.2 mo, HR = 4.4, 
95%CI: 1.7-11.7, P = 0.0013). OS: Overall survival; CTC: Circulating tumor cell.
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uPAR expressing cells, can escape standard methods 
of isolation reliant on epithelial markers[22]. Indeed 
Vishnoi et al[23]. has previously reported the isolation 
of subsets of EpCAM-negative, uPAR and integrin β1 
positive breast cancer CTCs, which further supports the 
concept of CTC heterogeneity[23]. Ultimately, we have 
successfully stained for a novel biomarker, uPAR, which 
further supports our cryopreservation method as a valid 
CTC isolation approach. 
One important concern with cryopreservation is the 
potential for loss of CTCs due to cell loss during freezing, 
storage, or thawing. In a study by Nejlund et al[20], tumor 
cell recovery from cryopreserved spiked tumor cells in 
normal controls was variable, with up to a 40% tumor 
cell loss. However in clinical samples using matched 
fresh and cryopreserved specimens from the same 
patient, there was no consistent loss of CTCs, with the 
variation in CTC enumeration similar to those seen in 
paired fresh samples in other studies[2,20]. Friedlander 
et al[21] found that cryopreservation of PBMCs had no 
significant effect on the cell recovery from patients with 
metastatic prostate cancer. We noted a small loss of 
CTCs associated with cryopreservation, however this 
was predominately in samples with large numbers 
of CTCs (> 50), where loss of some CTCs is more 
acceptable than samples with low CTC counts. We 
noted samples with high numbers of CTCs were more 
prone to cell clumping despite benzonase. This is 
normally due to the release of viscous DNA from cell 
lysis on thawing, leading to aggregates which prevent 
accurate CTC counting. We speculate that the higher 
disease burden in these patients, coupled with a 
corresponding systemic inflammatory response, lead 
to poorer cell integrity within the PBMCs of high CTC-
count samples. Some loss of CTCs in these samples 
will have little impact for prognostic and down-stream 
biomarker analysis purposes. There was no significant 
loss of CTCs in samples were the total CTC count was 
≤ 50 (P = 0.06).
Similar to previously published work, we found that 
the duration of cryopreservation was not correlated 
with number of isolated CTCs[20]. Moreover, we were 
able to isolate CTCs from specimens stored at -80 ℃ 
for over two years, suggesting cryopreservation is a 
suitable approach for long term projects that involve 
biobanking of patient samples.
Even when using cryopreservation prior to CTC 
isolation, we found higher numbers of CTCs (median 
CTC count 17) and a higher number of patient samples 
with CTCs (98%) compared to other studies using 
EpCAM based CTC capture in gastroesophageal 
cancer[10-12,24]. The correlation of CTC numbers with 
disease progression implies that the CTCs we identified 
are indeed disease related. Increased CTC counts 
are consistent with the higher reported sensitivity 
of the IsoFlux system compared to other platforms, 
particularly in isolating CTCs with a lower expression of 
EpCAM[14-16]. Our results confirm, in the largest cohort 
of patients reported to date, that a high CTC count (> 
17) in cryopreserved specimen was an independent 
prognostic factor associated with poorer OS (HR = 
3.7). As expected from the minimal CTC loss during 
cryopreservation, these data indicate that indeed 
our method is suitable for delayed and centralised 
CTC analysis which could help recruiting patients for 
major clinical trials. In this setting it would be advanta-
geous compared to fixation of blood which allows 
CTC processing delayed by only several days rather 
than long term biobanking. We are currently testing if 
cryopreservation is also able to overcome limitations 
associated with using fixative for molecular down-
stream analysis of CTCs that involves nucleic acid 
extraction[4,5].
In conclusion, we have tested a robust PBMC cryopre-
servation protocol that allows successful CTC isolation 
even 2 years post freezing. Cryopreservation of CTCs is 
feasible, with a small loss of tumor cells predominantly 
in samples with a high CTC load. Enumeration of CTCs 
from cryopreserved samples remained a clinically im-
portant prognostic biomarker. Cryopreservation may 
assist with the wider incorporation of CTC collection 
and analysis in biobanking, retrospective studies, and 
large international clinical trials, by facilitating specimen 
storage, bulk transporting, and batch processing. It 
may also help to develop diagnostic settings that can 
service even remote patients with diagnostic CTC data 
potentially relevant for their disease management.
ARTICLE HIGHLIGHTS
Research background
A persisting challenge to the field of circulating tumor cell (CTC) research is the 
requirement for prompt analysis of samples at specialised centres. This has 
presented significant logistical challenges to researchers, compounded by the 
significant expertise, time and laboratory resources required for CTC analysis.
Research motivation
Current methods to overcome this issue, such as fixation of blood samples, 
extend the time for CTC processing for several days, but may interfere with 
downstream molecular analyses.
Cryopreservation of patient samples permits the wider incorporation of 
CTC collection and analysis in biobanking, retrospective studies, and large 
international clinical trials, by facilitating specimen storage, bulk transporting, 
and batch processing. However, up to now, there has been little research in 
how cryopreservation affects CTC recovery, and whether cryopreservation 
retains predictive value of CTCs.
Research objectives
The primary objective of our study was to investigate the feasibility and reliability 
of delayed CTC isolation from cryopreserved peripheral blood mononuclear 
cells (PBMCs) layer. This was determined by percentage of CTC loss during 
cryopreservation and thawing, and clinical validity of CTC enumeration from 
cryopreserved samples. 
Research methods
CTCs were isolated from 7.5 mL blood samples collected from patients with 
gastroesophageal adenocarcinoma using EpCAM based immunomagnetic 
capture with the IsoFlux platform. CTC loss with cryopreservation was 
determined by comparing CTC enumeration from matched cryopreserved 
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and freshly processed blood samples collected during the same blood draw. 
CTCs isolated from pre-treatment cryopreserved PBMCs were examined for 
association with clinicopathological variables and survival outcomes. 
Research results
We found a minor loss of tumor cells in matched cryopreserved and freshly 
processed samples, mostly in samples with high CTC counts. A high CTC 
count isolated from cryopreserved PBMCs remained a statistically significant 
independent prognostic factor in gastroesophageal cancer.  
Research conclusions
Our study demonstrates a feasible and robust protocol facilitating CTC isolation 
from cryopreserved PBMCs even after 2 years post freezing. Our results have 
immediate applicability in the design and conduct of translational studies, 
as it facilitates incorporation of CTC analysis in large international trials and 
biobanking projects. 
Research perspectives
There is an increasing variety of techniques used for CTC isolation described 
in the literature. While the current work confirms the reliability of CTC isolation 
from cryopreserved samples using immunomagnetic separation, further work 
needs to be undertaken to confirm its suitability for other isolation approaches.   
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